Going Full time into Investing

This article provides a glimpse into an individual's investment strategy and stock selections across various sectors, which can be a starting point for other investors' due diligence.

Neutral to slightly positive for mentioned stocks as they gain visibility, but requires independent analysis.

For Indian markets, this story mainly matters for NEULANDLAB, NAZARA, 3BB and the pharma pocket. The current signal is mixed, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Included in a personal portfolio as a '10x in 10 years bet'. Included in a personal portfolio as a 'compounder'. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Investor transitioning to full-time investing with a portfolio deployed as of March 31, 2026.
• •Portfolio includes '10x in 10 years bets', compounders, and turnarounds.
• •Specific stocks mentioned: Neuland Laboratories, Nazara Technologies, 3B BlackBio, RateGain, IndiaMART, IGL, Nykaa, Aarti Pharmalabs, CDSL, Deepak Nitrite, Saregama.
• •Risk flag: This is a personal portfolio and may not suit all risk profiles.
• •Risk flag: The investor has 'no benchmarks to beat, no customers to answer to', implying a high-risk tolerance.